Claims for Patent: 10,308,715

Summary for Patent: 10,308,715

Title:	Antibody targeting osteoclast-related protein Siglec-15
Abstract:	To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like.
Inventor(s):	Hiruma; Yoshiharu (Tokyo, JP), Tsuda; Eisuke (Tokyo, JP)
Assignee:	DAIICHI SANKYO COMPANY, LIMITED (Tokyo, JP)
Application Number:	15/729,947
Patent Claims:	1. An antibody or an antigen binding fragment thereof, comprising the same Complementarity Determining Regions (CDRs) as a monoclonal antibody produced by hybridoma #32A1, wherein the antibody or antigen binding fragment thereof specifically binds to any one of the following polypeptides (a)-(h), or any combination thereof, and inhibits osteoclast formation and/or osteoclastic bone resorption: (a) the amino acid sequence of SEQ ID NO: 2; (b) amino acid residues 21 to 328 of the amino acid sequence of SEQ ID NO: 2; (c) amino acid residues 1 to 260 of the amino acid sequence of SEQ ID NO: 2; (d) amino acid residues 21 to 260 of the amino acid sequence of SEQ ID NO: 2; (e) the amino acid sequence of SEQ ID NO: 4; (f) amino acid residues 21 to 341 of the amino acid sequence of SEQ ID NO: 4; (g) amino acid residues 1 to 258 of the amino acid sequence of SEQ ID NO: 4; or (h) amino acid residues 21 to 258 of the amino acid sequence of SEQ ID NO: 4. 2. The antibody or antigen binding fragment of claim 1, wherein the antibody is a monoclonal antibody. 3. The antibody or antigen binding fragment of claim 1, wherein the antibody is an IgG antibody. 4. A pharmaceutical composition comprising an antibody or antigen binding fragment according to claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable diluent or carrier. 5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition further comprises at least one agent selected from the group consisting of bisphosphonate, active vitamin D.sub.3, calcitonin, hormones, ipriflavone, vitamin K.sub.2 (menatetrenone), calcium, PTH (parathyroid hormone), nonsteroidal anti-inflammatory agent, soluble TNF receptor, anti-TNF-.alpha. antibody or an antigen binding fragment thereof, anti-PTHrP (parathyroid hormone-related protein) antibody or an antigen binding fragment thereof, anti-IL-6 receptor antibody or an antigen binding fragment thereof, anti-RANKL antibody or an antigen binding fragment thereof, and OCIF (osteoclastogenesis inhibitory factor).

Details for Patent 10,308,715

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2027-10-11